Capricor completes BLA submission to the FDA for the approval of its investigational cell therapy for Duchenne cardiomyopathy

Capricor Therapeutics, which received early funding from CureDuchenne, has completed a Biologics License Application (BLA) with the US FDA, seeking full approval of deramiocel for individuals with Duchenne cardiomyopathy.  Deramiocel (CAP-1002) consists of cardiosphere-derived cells which secrete extracellular vesicles known as exosomes, to promote immunomodulatory and antifibrotic actions.

Link to press release:  https://www.capricor.com/investors/news-events/press-releases/detail/303/capricor-therapeutics-completes-submission-of-biologics